Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02891408 · ClinicalTrials.gov registry record · Phase 1

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

A Phase 1 study, sponsored by Gilead Sciences.

Completed
Registry status
Phase 1
Development phase
74
Enrollment target

NCT02891408: Completed Phase 1 study, sponsored by Gilead Sciences.

NCT02891408 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 74 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02891408, a Phase 1 study, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 1
Development phase
74 participants
Enrollment target

Study Summary

The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic impairment and to evaluate the single-dose PK of fenofibrate in adults with normal hepatic function and mild hepatic impairment.

Primary Outcome

AUClast is defined as the concentration of drug from time zero to the last observable concentration. The PK of fenofibric acid was evaluated in participants with mild hepatic impairment and matched participants with normal hepatic function (Cohort 4).

Interventions

  • DRUG Fenofibrate
  • DRUG Firsocostat

Trial Details

FieldValue
Enrollment Target 74 participants
Start Date 2016-09-23
Est. Completion 2019-05-13
Phase Phase 1
Gilead Sciences

504 total trials

What the finished NCT02891408 record still lists

NCT02891408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher).

The record links to 0 conditions, and to 2 interventions - of which Fenofibrate is the first listed.

NCT02891408 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02891408 about?

NCT02891408 is a clinical study titled "Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function". The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic impairment and to evaluate the single-dose PK of fenofibrate in adults with normal hepatic function and mild hepatic...

What is the current status of trial NCT02891408?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2016-09-23. Estimated completion is 2019-05-13.

What interventions are being tested in trial NCT02891408?

The interventions under investigation include: Fenofibrate (DRUG), Firsocostat (DRUG).

Who is sponsoring clinical trial NCT02891408?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02891408's enrollment target sits among peer trials

74 725th of 2000 higher than 1,269 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03422731 · 74 participants · Early Phase 1

    Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

  • NCT03804853 · 74 participants · NA

    Rehabilitation Following Reverse Total Shoulder Arthroplasty

  • NCT04065776 · 74 participants · NA

    Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma

  • NCT04771156 · 74 participants · Phase 4

    Ketorolac in Palatoplasty

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02891408, the US trial registry maintained by the National Library of Medicine. NCT02891408 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.